Write in a clean editor, then format for Journal of Hematology & Oncology in one click — DocuGuru applies the official BMC (BioMed Central) template with numbered references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Journal of Hematology & Oncology is a peer-reviewed journal published by BMC (BioMed Central), covering CAR-T cell therapy research, Acute Myeloid Leukemia Research, Lymphoma Diagnosis and Treatment. Over its lifetime it has published 2,199 papers, which have received 211,761 citations.
| Publisher | BMC (BioMed Central) |
|---|---|
| Reference style | Numbered (Vancouver) Numbered — [1], [2] in the text 1. Smith A, Jones B, Lee C. A representative article title. Journal of Hematology & Oncology. 2023;12(3):45–58.
Formats any DOI in Journal of Hematology & Oncology style. No sign-up. |
| Publishes research in | CAR-T cell therapy research Acute Myeloid Leukemia Research Lymphoma Diagnosis and Treatment Cancer Immunotherapy and Biomarkers Immune Cell Function and Interaction |
| ISSN | 1756-8722 |
| Citation impact (2-yr) | 30.96 |
| h-index | 230 |
| i10-index | 1,879 |
| Article processing charge | $3,422 |
| Open access | Yes — indexed in DOAJ |
| Top institutions publishing here | Chinese Academy of Medical Sciences & Peking Union Medical College |
| Journal website | link.springer.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Ferroptosis is a novel type of cell death with distinct properties and recognizing functions involved in physical conditions or various diseases including cancers. The fast-growing studies of ferroptosis in cancer have boosted a perspective for its usage in cancer therapeutics. Here, we review the current findings of ferroptosis regulation and especially focus on the function…
CD44, a non-kinase transmembrane glycoprotein, is overexpressed in several cell types including cancer stem cells and frequently shows alternative spliced variants that are thought to play a role in cancer development and progression. Hyaluronan, the main ligand for CD44, binds to and activates CD44 resulting in activation of cell signaling pathways that induces cell proliferation,…
Tumor metastasis is a major contributor to the death of cancer patients. It is driven not only by the intrinsic alterations in tumor cells, but also by the implicated cross-talk between cancer cells and their altered microenvironment components. Tumor-associated macrophages (TAMs) are the key cells that create an immunosuppressive tumor microenvironment (TME) by producing cytokines,…
The aberrant Wnt/β-catenin signaling pathway facilitates cancer stem cell renewal, cell proliferation and differentiation, thus exerting crucial roles in tumorigenesis and therapy response. Accumulated investigations highlight the therapeutic potential of agents targeting Wnt/β-catenin signaling in cancer. Wnt ligand/ receptor interface, β-catenin destruction complex and TCF/β-catenin transcription complex are key components of the cascade and have…
In recent years, cancer immunotherapy based on immune checkpoint inhibitors (ICIs) has achieved considerable success in the clinic. However, ICIs are significantly limited by the fact that only one third of patients with most types of cancer respond to these agents. The induction of cell death mechanisms other than apoptosis has gradually emerged as a…
